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chemotherapy with docetaxel (DOC) and cisplatin
(CDDP) using superselective intra-arterial
infusion via superficial temporal arteryKenji Mitsudo a,*, Iwai Tohnai b, Yasushi Fujimoto c, Yoshihiro Sawaki d,
Tomotaka Sugimura a, Hiroaki Nishiguchi a, Takafumi Fukui a,
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d Department of Oral and Maxillofacial Surgery, Nakatsugawa Municipal General Hospital, JapanReceived 1 February 2006; accepted 2 May 2006Summary Primary leiomyosarcomas in the head and neck are rare tumors. We report a case of
maxillary leiomyosarcoma in a 35-year-old male. The patient was referred to our hospital in
October 2003, and diagnosed with leiomyosarcoma, originating around the left maxillary sinus.
Superselective intra-arterial chemotherapy with docetaxel (DOC) and cisplatin (CDDP) via a
superficial temporal artery was employed as preoperative therapy. The tumor decreased in size
to less than 50% of its initial volume after this therapy. Total maxillectomy was performed, and
70–80% of tumor cells showed degeneration and necrosis. The patient has been free of disease
for 2 years after operation. Chemotherapy is thought to have little effect in achieving local con-
trol of leiomyosarcomas, however, superselective intra-arterial chemotherapy was very bene-
ficial in this patient.c 2006 Elsevier Ltd. All rights reserved.
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Leiomyosarcomas are malignant mesenchymal neoplasms of
smooth muscle origin that account for 5–10% of all soft
tissue sarcomas. Most of these tumors occur in the uterus,.
Leiomyosarcoma of the maxilla 259gastrointestinal tract, and retroperitoneum. Only 3–10% oc-
cur in head and neck region.1 Leimyosarcomas of the head
and neck are characterized by aggressiveness and a poor
prognosis, and there is no established therapeutic strategy,
especially for patients for whom surgery is not appropriate.2
Chemotherapy has been employed but is not beneficial in
most instances, and it seems appropriate only for the palli-
ation of inoperable tumors.3
We report a new treatment for maxillary leiomyosar-
coma, in which the sarcoma was effectively treated with
superselective intra-arterial chemotherapy via a superficial
temporal artery using docetaxel (DOC) and cisplatin (CDDP).
The patient has survived for 2 years since the operation.Case report
A 35-year-old man was referred to our hospital in October
2003 because of left facial and maxillary gingival swelling.Figure 1 (A) A soft, nodular tumor, measuring 30 mm in diamete
eosin-stained sections of biopsy specimens showed extensive prol
nuclei (·200). (C), (D). Immunohistochemical staining showed the t
vimentin (D) (·200).He had first noticed these symptoms in August 2003. He
went to a neighborhood dentist, and his left upper second
premolar was extracted based on a diagnosis of periodontal
disease. The patient’s general condition and laboratory
findings were unremarkable. Clinical findings revealed an
ulcerated mass originating from the left maxillary gum.
The mass measured 30 mm in diameter and was soft and
tender to palpation (Fig. 1A). The left upper first premolar
and first molar located near the mass were easy to move.
Incisional biopsy revealed extensive prolifelation of neo-
plastic spindle cells with poorly differentiated nuclei
(Fig. 1B). Immunohistochemical staining showed the tumor
cells to be positive for alpha smooth-muscle actin
(Fig. 1C) and vimentin (Fig. 1D), and negative for S-100,
CD34 and factor VIII.
A CT scan of the maxilla revealed a space-occupying
mass in the right maxillary sinus measuring 50 · 30 ·
25 mm. The mass extended inferiorly to involve the maxil-
lary alveolar process (Fig. 2A). Superiorly, disruption ofr is evident in the left maxillary gingiva. (B) Hematoxylin and
iferation of neoplastic spindle cells with poorly differentiated
umor cells to be positive for alpha smooth-muscle actin (C) and
Figure 2 (A) Tumors of 30 mm in diameter from the left maxilla to buccal region. (B) The tumors filled the left maxillary sinus, and
disruption of the orbital floor was seen (‹). (C) Angiogram of superselective intra-arterial infusion via left superficial temporal
artery. The tip of the catheter was inserted into left maxillary artery (‹: tip of the catheter). The contrast medium was seen to be
flowing only in the maxillary artery. (D) Tumor stain was seen with the use of contrast medium (‹: tumor stain).
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(Fig. 2B). The neck CT did not show pathologic lymph node
enlargement. The distant metastasis workup was negative.
We had previously used superselective intra-arterial che-
motherapy for patients with oral cancer, and employed with
the present patient. A catheter was inserted superselec-
tively into the left maxillary artery via the left superficial
temporal artery.4 The tip of the catheter was inserted into
the left maxillary artery (Fig. 2C). Tumor stain was seen
with the use of contrast medium (Fig. 2D). This treatment
consisted of superselective intra-arterial chemotherapy
(DOC 30 mg/body, CDDP 40 mg/body) for 3 days as a preop-
erative therapy. As a result, the tumor decreased in size to
less than 50% of its initial volume (Fig. 3A). Grade 2 anorexia
toxicity was observed following this therapy (NationalCancer Institute-Common Toxicity Criteria, 2004). Based
on these radiographic and microscopic findings, the patient
underwent a left total maxillectomy. Immediate recon-
struction of the defect was performed with an abdominal
free flap. Seventy to 80% of tumor cells showed degenera-
tion and necrosis (Fig. 3B), and the surgical margins were
tumor-free. The patient has been free of disease for 2 years
since the operation.Discussion
In cases of head and neck leiomyosarcoma, the success of
the initial surgical management is an important prognostic
factor, as complete surgical excision is associated with
Figure 3 (A) After preoperative superselective intra-arterial
chemotherapy, the tumor decreased in size to less than 50% of
its initial volume. (B) Microphotograpy of the surgical speci-
men. Degeneration or necrosis was seen in 70–80% of tumor
cells. Apoptosis was also seen in some of the tumor cells (‹)
(H&E, ·200).
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resection with microscopically tumor-free margins is of par-
amount importance for long-term survival. Adjuvant radia-
tion treatment or chemotherapy appears to be ineffective
in achieving local control when there is residual tumor
postoperatively.5,6
In previously reported studies, cisplatin was found to be
an inactive drug in patients with recurrent or advanced lei-
omyosarcoma of the uterus, both in those previously ex-
posed and unexposed to chemotherapy.7 Combined
ifosfamide and doxorubicin yielded a 30.3% response rate.8
Paclitaxel produced a response rate of 31.3% in one gyneco-
logic oncology group study9 while liposomal doxorubicin
produced a 16% response rate in another.10 Gemcitabine
has been one of the few agents showing activity in these tu-mors with an observed response rate of 20.5%.11 Hensley
et al. combined gemcitabine with docetaxel and reported
a response rate of 53% in 34 patients, some of whom had
failed doxorubicin therapy.12
Superselective intra-arterial chemotherapy for curative
treatment of head and neck cancer has undergone a revival
in the last decade. It is mainly used concurrently with radi-
ation13–16 or alone.17 The main drugs used mainly have been
cisplatin or carboplatin. Administration was either continu-
ous with a temporal retrograde approach14,15,17 or by re-
peated bolus infusions with a transfemoral anterograde
approach.13 The main aim of these trials was organ preser-
vation in patients with advanced cancer. Superselective in-
tra-arterial chemotherapy via a superficial temporal artery
was developed by Tohnai et al.,4 and has become feasible
for daily concurrent radiotherapy and chemotherapy for ad-
vanced head and neck cancer. Tohnai used this method with
35 oral cancer patients as a preoperative therapy. Clinical
effects were seen in all 35 patients (100%), and pathological
CR and PR of the resected tumor were 88.6% and 11.4%,
respectively. The 5-year cumulative survival rate was
78.8%.18 To our knowledge, there is only one report other
than the present one on superselective intra-arterial che-
motherapy for a leiomyosarcoma of the head and neck.2
In this case, good long-term results were achieved with
the use of external radiotherapy and hyperthermia in com-
bination with superselective intra-arterial chemotherapy.
Although chemotherapy and radiotherapy are generally con-
sidered to be ineffective for leiomyosarcomas of the head
and neck, superselective intra-arterial chemotherapy was
very beneficial in the present patient. This method also
seems promising for cases of recurrent or advanced
leiomyosarcoma.References
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